VX17-661-116 A Phase 3, Open Label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Tezacaftor in Combination if Ivacaftor in Subjects with Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous f